Rein Therapeutics Statistics Share Statistics Rein Therapeutics has 23.26M
shares outstanding. The number of shares has increased by 7.36%
in one year.
Shares Outstanding 23.26M Shares Change (YoY) 7.36% Shares Change (QoQ) 4.99% Owned by Institutions (%) 99.99% Shares Floating 18.55M Failed to Deliver (FTD) Shares 17,000 FTD / Avg. Volume 13.49%
Short Selling Information The latest short interest is 21.32K, so 0.09% of the outstanding
shares have been sold short.
Short Interest 21.32K Short % of Shares Out 0.09% Short % of Float 0.09% Short Ratio (days to cover) 1
Valuation Ratios PE Ratio 0 Forward PE -1.43 PS Ratio 0 Forward PS 0.4 PB Ratio 0 P/FCF Ratio 0 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Rein Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 2.38,
with a Debt / Equity ratio of 0.
Current Ratio 2.38 Quick Ratio 2.38 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-5.72M Employee Count 11 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax -1.54M Effective Tax Rate 2.4%
Stock Price Statistics The stock price has increased by null% in the
last 52 weeks. The beta is 1.14, so Rein Therapeutics's
price volatility has been higher than the market average.
Beta 1.14 52-Week Price Change n/a 50-Day Moving Average 1.2 200-Day Moving Average 1.72 Relative Strength Index (RSI) 49.73 Average Volume (20 Days) 126,057
Income Statement
Revenue n/a Gross Profit -63K Operating Income -65.11M Net Income -62.88M EBITDA -28.05M EBIT -28.11M Earnings Per Share (EPS) -3.51
Full Income Statement Balance Sheet The company has 12.87M in cash and 0 in
debt, giving a net cash position of 12.87M.
Cash & Cash Equivalents 12.87M Total Debt n/a Net Cash n/a Retained Earnings -351.4M Total Assets 57.48M Working Capital -1.09M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -22.29M
and capital expenditures 0, giving a free cash flow of -22.29M.
Operating Cash Flow -22.29M Capital Expenditures n/a Free Cash Flow -22.29M FCF Per Share -1242.67
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields RNTX does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for RNTX is $10,
which is 740.3% higher than the current price. The consensus rating is "Hold".
Price Target $10 Price Target Difference 740.3% Analyst Consensus Hold Analyst Count 2
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Nov 11, 2022. It was a
backward
split with a ratio of 1:20.
Last Split Date Nov 11, 2022 Split Type backward Split Ratio 1:20
Scores Altman Z-Score -9.3 Piotroski F-Score 1
